Cargando…

SARS-CoV-2 antibody progression and neutralizing potential in mild symptomatic COVID-19 patients – a comparative long term post-infection study

BACKGROUND: Since December 2019, SARS-CoV-2 has been keeping the world in suspense. Rapid tests, molecular diagnosis of acute infections, and vaccination campaigns with vaccines are building blocks of strategic pandemic control worldwide. For laboratory diagnostics, the quantification of the antibod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brehm, Jessica, Spaeth, Alexander, Dreßler, Lars, Masetto, Thomas, Dannenberg, Rainer, Peter, Christoph, Grimmler, Matthias
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428854/ https://www.ncbi.nlm.nih.gov/pubmed/36059441 http://dx.doi.org/10.3389/fimmu.2022.915338

Ejemplares similares

Characterization of the Diagnostic Performance of a Novel COVID-19 PETIA in Comparison to Four Routine N-, S- and RBD-Antigen Based Immunoassays
por: Spaeth, Alexander, et al.
Publicado: (2021)

Vaccine-induced SARS-CoV-2 antibody response: the comparability of S1-specific binding assays depends on epitope and isotype discrimination
por: Schest, Silvia, et al.
Publicado: (2023)

Bioinformatical Design and Performance Evaluation of a Nucleocapsid- and an RBD-Based Particle Enhanced Turbidimetric Immunoassay (PETIA) to Quantify the Wild Type and Variants of Concern-Derived Immunoreactivity of SARS-CoV-2
por: Wey, Leoni, et al.
Publicado: (2023)

Letter to the Editor regarding “Development of an antibody-free ID-LC MS method for the quantification of procalcitonin in human serum at sub-microgram per liter level using a peptide-based calibration”
por: Tölke, Sebastian-Alexander, et al.
Publicado: (2021)

Recent Progress toward Engineering HIV-1-Specific Neutralizing Monoclonal Antibodies
por: Sun, Ming, et al.
Publicado: (2016)

Asymptomatic and Mild SARS-CoV-2 Infections Elicit Lower Immune Activation and Higher Specific Neutralizing Antibodies in Children Than in Adults
por: Petrara, Maria Raffaella, et al.
Publicado: (2021)

Virological and Clinical Determinants of the Magnitude of Humoral Responses to SARS-CoV-2 in Mild-Symptomatic Individuals
por: Pradenas, Edwards, et al.
Publicado: (2022)

Asymptomatic or mild symptomatic SARS-CoV-2 infection elicits durable neutralizing antibody responses in children and adolescents
por: Garrido, Carolina, et al.
Publicado: (2021)

CD25 as a unique marker on human basophils in stable-mildly symptomatic allergic asthma
por: Iype, Joseena, et al.
Publicado: (2023)

Neutralization-Enhancing RF Antibodies for HIV Vaccines
por: Suslov, Konstantin V.
Publicado: (2014)

Broadly Neutralizing Antibodies for HIV-1 Prevention
por: Walsh, Stephen R., et al.
Publicado: (2021)

Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset
por: Xiang, Tiandan, et al.
Publicado: (2021)

Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
por: Shrestha, Lok Bahadur, et al.
Publicado: (2021)

The molecular basis of the neutralization breadth of the RBD-specific antibody CoV11
por: Tolbert, William D., et al.
Publicado: (2023)

Antibody-Dependent Cellular Cytotoxicity (ADCC)-Mediating Antibodies Constrain Neutralizing Antibody Escape Pathway
por: Mielke, Dieter, et al.
Publicado: (2019)

Cross-reactive broadly neutralizing antibodies: timing is everything
por: Euler, Zelda, et al.
Publicado: (2012)

Non-Neutralizing Antibodies Directed against HIV and Their Functions
por: Mayr, Luzia M., et al.
Publicado: (2017)

Editorial: Neutralizing Antibodies in the Prevention and Treatment of COVID-19
por: Razonable, Raymund R., et al.
Publicado: (2022)

A protective role of HTLV-1 gp46-specific neutralizing and antibody-dependent cellular cytotoxicity-inducing antibodies in progression to adult T-cell leukemia (ATL)
por: Tanaka, Yuetsu, et al.
Publicado: (2022)

Single-Domain Antibodies Efficiently Neutralize SARS-CoV-2 Variants of Concern
por: Favorskaya, Irina A., et al.
Publicado: (2022)

Neutralizing Monoclonal Antibodies to Fight HIV-1: On the Threshold of Success
por: Jaworski, Juan Pablo, et al.
Publicado: (2017)

Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies
por: Lavie, Muriel, et al.
Publicado: (2018)

Single Domain Antibody application in bacterial infection diagnosis and neutralization
por: Qin, Qian, et al.
Publicado: (2022)

Neutralizing antibody response in mild COVID-19
por: van der Heide, Verena
Publicado: (2020)

Dengue virus neutralizing antibody: a review of targets, cross-reactivity, and antibody-dependent enhancement
por: Sarker, Animesh, et al.
Publicado: (2023)

A Potent and Protective Human Neutralizing Antibody Against SARS-CoV-2 Variants
por: Shan, Sisi, et al.
Publicado: (2021)

Hexamerization of Anti-SARS CoV IgG1 Antibodies Improves Neutralization Capacity
por: Pande, Kalyan, et al.
Publicado: (2022)

Neutralizing Anti-Rituximab Antibodies and Relapse in Membranous Nephropathy Treated With Rituximab
por: Boyer-Suavet, Sonia, et al.
Publicado: (2020)

Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells
por: Hong, Junping, et al.
Publicado: (2022)

Convergent antibody responses are associated with broad neutralization of hepatitis C virus
por: Skinner, Nicole E., et al.
Publicado: (2023)

Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2
por: Konwarh, Rocktotpal
Publicado: (2020)

A Rapid and Efficient Screening System for Neutralizing Antibodies and Its Application for SARS-CoV-2
por: Han, Xiaojian, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies
por: Tada, Takuya, et al.
Publicado: (2022)

A Structural Landscape of Neutralizing Antibodies Against SARS-CoV-2 Receptor Binding Domain
por: Niu, Ling, et al.
Publicado: (2021)

Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
por: Schlickeiser, Stephan, et al.
Publicado: (2021)

The impact of CoronaVac on the neutralization breadth and magnitude of the antibody response to SARS-CoV-2 viruses
por: Zhang, Lu, et al.
Publicado: (2022)

SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis
por: Liew, Mabel Nyit Yi, et al.
Publicado: (2023)

HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function
por: Richardson, Simone I., et al.
Publicado: (2021)

Comprehensive Comparison of the Capacity of Functionalized Sepharose, Magnetic Core, and Polystyrene Nanoparticles to Immuno-Precipitate Procalcitonin from Human Material for the Subsequent Quantification by LC-MS/MS
por: Masetto, Thomas, et al.
Publicado: (2023)

Effects of methylsulfonylmethane and neutralizing anti–IL-10 antibody supplementation during a mild Eimeria challenge infection in broiler chickens
por: Rasheed, M. S. Abdul, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tshu1lt41bqv9r89g1mpqf4lr7